Developing Oral LT3 Therapy for Heart Failure - HFrEF

Exclusion Criteria

• •1. Hypertrophic or restrictive cardiomyopathy
• •2. Uncorrected severe primary valvular disease
• •3. Arrhythmia that results in irregular heart rate
• •4. Inability to perform VO2max exercise testing
• •5. Severe lung disease, including treatment with oral steroids within past 6 months for exacerbation of obstructive lung disease or use of daytime supplemental oxygen
• •6. Serum creatinine \> 3.0 mg/dL
• •7. History of cirrhosis
• •8. LVAD use
• •9. Heart failure hospitalization within past month
• •10. Acute coronary syndrome, coronary intervention or ablation therapy within past 2 months or cardiac surgery, percutaneous repair of a valve or septal defect repair within the past 6 months
• •11. Taking thyroid extract, LT4, LT3, amiodarone, or medication that affects the absorption or metabolism of thyroid hormone; gastrointestinal conditions that affect the absorption of thyroid hormone
• •12. If female, current or planned pregnancy within the timeframe of study participation
• •13. Any medical condition that in the opinion of the investigator, will interfere with the safe completion of the study.